TY  - GEN
AU  - Hernández-Prat,Anna
AU  - Rodriguez-Vida,Alejo
AU  - Juanpere-Rodero,Nuria
AU  - Arpi,Oriol
AU  - Menéndez,Silvia
AU  - Soria-Jiménez,Luis
AU  - Martínez,Alejandro
AU  - Iarchouk,Natalia
AU  - Rojo,Federico
AU  - Albanell,Joan
AU  - Brake,Rachael
AU  - Rovira,Ana
AU  - Bellmunt,Joaquim
TI  - Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
SN  - 1557-3125
PY  - 2020///0617
KW  - Administration, Oral
KW  - Animals
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Benzoxazoles
KW  - Cell Line, Tumor
KW  - Cell Proliferation
KW  - drug effects
KW  - Cell Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug Synergism
KW  - Humans
KW  - Imidazoles
KW  - Male
KW  - Mechanistic Target of Rapamycin Complex 1
KW  - antagonists & inhibitors
KW  - Mechanistic Target of Rapamycin Complex 2
KW  - Mice
KW  - Morpholines
KW  - Paclitaxel
KW  - Pyridines
KW  - Pyrimidines
KW  - Urinary Bladder Neoplasms
KW  - drug therapy
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1541-7786.MCR-18-0923
ER  -